Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Providence County
    4. ›
  4. Providence
    5. ›
  5. ProThera Biologics, Inc.

ProThera Biologics, Inc.

Company claim

Is this your business?

Get access!

Company Details

Name: ProThera Biologics, Inc.
Jurisdiction: Rhode Island
Entity type: Domestic Profit Corporation
Status: Activ
Date of Organization in Rhode Island: 12 Jul 2001 (24 years ago)
Identification Number: 000271999
ZIP code: 02903
City: Providence
County: Providence County
Purpose: BIOTHERAPEUTICS RESEARCH AND DEVELOPMENT COMPANY
Principal Address: Google Maps Logo 349 EDDY STREET, PROVIDENCE, RI, 02903, USA

Industry & Business Activity

NAICS

541714 Research and Development in Biotechnology (except Nanobiotechnology)

This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Learn more at the U.S. Census Bureau

Companies doing Research and development in biotechnology (except nanobiotechnology)

Agent

Name Role Address
YOW-PIN LIM Agent 349 EDDY STREET, PROVIDENCE, RI, 02903, USA

CEO

Name Role Address
YOW-PIN LIM CEO 349 EDDY STREET PROVIDENCE, RI 02903 USA

DIRECTOR

Name Role Address
THORNE SPARKMAN DIRECTOR 349 EDDY STREET PROVIDENCE, RI 02903 USA
YOW-PIN LIM DIRECTOR 349 EDDY STREET PROVIDENCE, RI 02903 USA
RICHARD ANDREWS DIRECTOR 349 EDDY STREET PROVIDENCE, RI 02903 USA
PATRICIA MILOS DIRECTOR 349 EDDY STREET PROVIDENCE, RI 02903 USA
MOSES GODDARD DIRECTOR 349 EDDY STREET PROVIDENCE, RI 02903 USA

SECRETARY

Name Role Address
NAYEN GRACE LEE SECRETARY 349 EDDY STREET PROVIDENCE, RI 02903 USA

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Phone Number:
401-301-2046
E-mail Address:
yplim@protherabiologics.com
Contact Person:
YOW-PIN LIM
User ID:
P0711684
SBA Link:
View company profile on SBA website

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

CAGE Code:
47QA1
UEI Expiration Date:
2020-10-29

Business Information

Activation Date:
2019-10-30
Initial Registration Date:
2005-11-15

Central Index Key

A CIK (Central Index Key) number is a unique identifier assigned by the U.S. Securities and Exchange Commission (SEC) to companies that: Are publicly traded on U.S. stock exchanges, File reports with the SEC.

Note: Having a CIK number indicates that: The company is registered with the SEC, Files regular financial reports (like 10-K, 10-Q), Must comply with federal securities laws and regulations, Has public shareholders, Makes financial information publicly available through SEC's EDGAR database.

CIK number:
0001659513
Phone:
401-331-9944
EDGAR Link:
View company profile on EDGAR website

Latest Filings

Form type:
D/A
File number:
021-302891
Filing date:
2019-01-08
File:
View File
Form type:
D
File number:
021-302891
Filing date:
2018-01-10
File:
View File
Form type:
D
File number:
021-252137
Filing date:
2015-12-01
File:
View File

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
47QA1
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-11-01
CAGE Expiration:
2029-11-01
SAM Expiration:
2025-10-30

Contact Information

POC:
YOW-PIN LIM

Form 5500 Series

Employer Identification Number (EIN):
710868235
Plan Year:
2023
Number Of Participants:
5
Plan Name:
401(K)
Sponsor's telephone number:
4013012046
File:
View File
Plan Administrator / Signatory:
YOW-PIN LIM(Plan administrator)
Plan Year:
2022
Number Of Participants:
6
Plan Name:
401(K)
Sponsor's telephone number:
4012235859
File:
View File
Plan Administrator / Signatory:
YOW-PIN LIM(Plan administrator)
Plan Year:
2021
Number Of Participants:
7
Plan Name:
401(K)
Sponsor's telephone number:
4013319944
File:
View File
Plan Administrator / Signatory:
DAWN MARSHALL(Plan administrator)

Events

Type Date Old Value New Value
Conversion 2007-10-31 ProThera Biologics, LLC on 10-31-2007 ProThera Biologics, Inc.

Filings

Number Name File Date
202447753550 Annual Report 2024-02-27
202336776040 Annual Report - Amended 2023-06-13
202336745550 Annual Report - Amended 2023-06-12
202336745190 Annual Report - Amended 2023-06-12
202333140970 Annual Report - Amended 2023-04-17

USAspending Awards / Financial Assistance

Business Type:
SMALL BUSINESS
Date:
2023-09-22
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
INTER-ALPHA INHIBITORS IN EXPERIMENTAL NECROTIZING ENTEROCOLITIS - NECROTIZING ENTEROCOLITIS (NEC) IS A DEVASTATING ACUTE INFLAMMATORY CONDITION OF THE GASTROINTESTINAL TRACT RESULTING IN INTESTINAL NECROSIS, SYSTEMIC SEPSIS AND MULTI-SYSTEM ORGAN FAILURE FOUND MOSTLY IN INFANTS BORN PREMATURELY. DESPITE MODERN MEDICAL ADVANCES IN THE PAST DECADE, THE ETIOLOGY REMAINS ELUSIVE AND MORBIDITY AND MORTALITY ARE STILL UNACCEPTABLY HIGH. IT HAS BEEN CONCLUDED THAT THE ONSET OF AN EXCESSIVE AND UNCONTROLLED INFLAMMATORY RESPONSE BY THE NEONATAL INTESTINE TO EXPOSURE TO LUMINAL BACTERIA IS A UNIFYING HYPOTHESIS THAT ENCOMPASSES MANY OF THE FACTORS THAT HAVE BEEN ASSOCIATED WITH THE DEVELOPMENT OF NEC. THE DEVELOPMENT OF EFFECTIVE THERAPEUTIC AGENTS THAT CAN TARGET AND MODULATE INFLAMMATORY RESPONSE MIGHT BE THE KEY TO REDUCE THE MORBIDITY AND MORTALITY ASSOCIATED WITH THIS LIFE-THREATENING DISEASE. INTER-ALPHA INHIBITOR PROTEINS (IAIP) ARE A FAMILY OF STRUCTURALLY RELATED SERINE PROTEASE INHIBITORS FOUND IN RELATIVELY HIGH CONCENTRATION IN HUMAN PLASMA. SUBSTANTIAL EVIDENCE SUGGESTED THAT IAIP PLAY AN IMPORTANT ANTI-INAMMATORY AND REGULATORY ROLE IN HOST RESPONSE AND SYSTEMIC INFLAMMATION. WE PREVIOUSLY REPORTED THAT CIRCULATING IAIP LEVELS ARE SIGNIFICANTLY DECREASED IN ADULT AND NEONATAL SEPSIS AND THE TOTAL IAIP LEVELS CORRELATED INVERSELY WITH MORTALITY IN ADULT PATIENTS WITH SEVERE SEPSIS. AS PART OF THE INNATE IMMUNE RESPONSE, IAIP PROTECT AGAINST THE DAMAGING EFFECTS OF PROTEASES AND ‘DANGER SIGNALS’ RELEASED DURING ACUTE SYSTEMIC INFLAMMATION FOLLOWING SEVERE INFECTIONS, BURN, TRAUMA AND INJURY. AS A CONSEQUENCE, IAIP ARE RAPIDLY CONSUMED AND EXCRETED IN THE URINE, LEADING TO A RAPID DECREASE IN PLASMA. IN SEVERAL ADULT AND NEWBORN ANIMAL MODELS OF SYSTEMIC INFLAMMATION AND SEPSIS, ADMINISTRATION OF IAIP TO NORMALIZE THE DECREASE LEVELS DEMONSTRATED SIGNIFICANT PROTECTIVE EFFECTS EVEN WHEN GIVEN AT DELAYED TIMEPOINTS STRONGLY INDICATING THAT IAIP IS POTENTIALLY USEFUL AS AN ADJUNCTIVE AGENT IN THE MANAGEMENT OF SYSTEMIC INFLAMMATION/SEPSIS. IN A STUDY TO DETERMINE THE ROLE OF IAIP IN NEC, WE FOUND A SIGNIFICANT DECREASE OF IAIP IN INFANTS WITH CLINICALLY PROVEN NEC (BELL’S STAGE II/III) COMPARED TO INFANTS WITH NON-SPECIFIC ABDOMINAL DISORDERS. WE HYPOTHESIZE THAT IAIP ADMINISTRATION MIGHT HAVE SIMILAR BENEFICIAL EFFECTS AS IN NEONATAL SEPSIS IN REDUCING THE MORBIDITY AND MORTALITY ASSOCIATED WITH NEC. PRELIMINARY STUDIES USING A MODEL BASED ON PANETH CELL ABLATION AND KLEBSIELLA PNEUMONIAE EXPOSURE TO INDUCE NEC-LIKE INJURY IN THE SMALL INTESTINE OF IMMATURE MICE CONFIRMED THAT ENDOGENOUS IAIP LEVELS WERE RAPIDLY DEPLETED SIMILAR TO THE OBSERVATION MADE IN INFANTS WITH NEC. THIS STUDY WILL OBTAIN PROOF-OF-CONCEPT OF A REPLACEMENT THERAPY USING HUMAN PLASMA DERIVED IAIP TO REDUCE MORBIDITY/MORTALITY ASSOCIATED WITH NEC. IF PROVEN, THIS NOVEL AND INNOVATIVE IAIP TREATMENT IN CONJUNCTION WITH THE PREDICTIVE TEST OF CIRCULATING IAIP LEVELS TO IDENTIFY HIGH RISK INFANTS WOULD OFFER A RATIONAL, TARGETED SOLUTION IN ADDRESSING A SERIOUS UNMET MEDICAL NEED FOR INFANTS SUFFERING FROM THIS DISEASE.
Obligated Amount:
$378,272
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2018-08-14
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS
Obligated Amount:
$3,016,411
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2015-09-16
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
THERAPEUTIC ROLE OF INTER-ALPHA INHIBITORS IN WOUND HEALING
Obligated Amount:
$224,688
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2017-06-09
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
INTER-ALPHA INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY
Obligated Amount:
$4,702,535
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0
Business Type:
SMALL BUSINESS
Date:
2014-06-17
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
INTER-ALPHA-INHIBITORS IN HYPOXIC-ISCHEMIC BRAIN INJURY
Obligated Amount:
$203,226
Face Value Of Loan:
$0
Total Face Value Of Loan:
$0

Reviews Leave a review

This company hasn't received any reviews.

Related by address

349 EDDY STREET, PROVIDENCE, RI, 02903, USA

LUCIDICOR INC,
Foreign Corporation
LUCIDICOR INC,, which currently Withdrawn, had registered address 349 EDDY STREET, PROVIDENCE, RI, 02903, USA.

Date of last update: 29 Jun 2025

Sources: Rhode Island Department of State

Privacy policy Policy
About us About us Business Directory
Contacts Contact us

© 2025 riorgs.com, Part of Big Data Integrated